Lectures and seminars OnkPat Friday Seminar: Translational development of theranostics, targeted radiopharmaceuticals for precision oncology

Host: Kasper Karlsson, Department of Oncology-Pathology

About Thuy Tran

Thuy Tran, PhD, Associate Professor, is a principal researcher, group leader of the TRANslational Theranostics Group at Karolinska Institutet and Head of the Theranostics Trial Center at Karolinska University Hospital. 

Her research focuses on the early development and clinical translation of targeted radiopharmaceuticals for precision oncology, spanning target discovery, radiochemistry, molecular imaging, radionuclide therapy, and early phase clinical trials. 

Her multidisciplinary team develops next-generation theranostic agents to improve the diagnosis and treatment of solid tumors through precision medicine.

Some examples of the targets that her team are developing radiopharmaceuticals for imaging and treatment include TROP2, HER2, PDGFRbeta, GRPR, and FAP.

Selected publications

HER2-targeted PET-imaging with [68Ga]Ga-ABY-025 to predict targeted-therapy response in HER2-expressing metastatic breast cancer: study protocol of a multicenter, prospective, open-label trial.
Altena R, Wiklander OPB, Romdhani NS, Kistner A, Klintman M, Skarping I, Lindman H, Rodriguez VS, Frisell O, Lindgren P, Bratteby K, Jussing E, Feldwisch J, Frejd FY, Cascales HS, Siikanen J, Hindorf C, Tran TA
Front Oncol 2026 ;16():1812711

Orthogonal Acyl Acceptor Substrate Pairs and hQC Improve Sequential Ligation by Peptide Asparaginyl Ligases.
Ng BWJ, Xia Y, Tran TA, Liu CF
Bioconjug Chem 2026 Jun;37(6):1231-1239

First-in-human experience with GRPR antagonist [68Ga]Ga-NOTA-PEG2-RM26 in prostate and breast cancer patients using PET/CT.
Bjäreback A, Jonmarker O, Tzortzakakis A, Jussing E, Li C, Altena R, Hindorf C, Orlova A, Axelsson R, Tran TA
EJNMMI Res 2025 Feb;15(1):12

Preclinical evaluation of [89Zr]Zr-DFO*-sacituzumab, a PET tracer for imaging of whole body TROP-2 expression as a potential selection tool for treatment with TROP-2 antibody drug conjugates (ADC).
Bratteby K; Smertinaite L; Omer S; Lu L; Milton S; Jussing E; Siikanen J; Samen E; Axelsson R; Foukakis T; Altena R; Tran TA. 
NUCLEAR MEDICINE AND BIOLOGY. 2023;126:10845